Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 3981315, 5 pages
https://doi.org/10.1155/2018/3981315
Research Article

Mitochondrial T16189C Polymorphism Is Associated with Metabolic Syndrome in the Mexican Population

1Laboratorio Multidisciplinario de Investigación, Escuela Militar de Graduados de Sanidad, Secretaría de la Defensa Nacional, CP 11200 Ciudad de México, Mexico
2Facultad de Estudios Superiores Cuautitlán Izcalli, UNAM, CP 54740 Cuautitlán, Estado de México, Mexico
3Universidad del Valle de México, Campus Lomas Verdes, CP 53220 Naucalpan de Juárez, Estado de México, Mexico
4Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional, CP 07738 Ciudad de México, Mexico
5Laboratorio de Biomedicina Molecular I, Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, CP 07320 Ciudad de México, Mexico

Correspondence should be addressed to Virginia Sánchez-Monroy; moc.liamtoh@71msykciv

Received 4 November 2017; Accepted 11 February 2018; Published 25 March 2018

Academic Editor: Gabriel R. Fries

Copyright © 2018 Elsa Saldaña-Rivera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Genetic factors, such as the mitochondrial DNA (mtDNA) T16189C polymorphism, have been associated with metabolic syndrome (MetS), but this association has not been studied in Mexico to date. The aim of the present study was to determine whether this polymorphism contributes to MetS in the Mexican population. We recruited 100 unrelated volunteer subjects who were divided into 2 groups: with MetS (MetS group) and without MetS (control group). All subjects were genotyped for the mtDNA T16189C polymorphism by polymerase chain reaction and sequencing. The mitochondrial T16189C polymorphism was detected in 24 (24%) of 100 subjects analyzed. The frequency of the mtDNA T16189C polymorphism was higher in the MetS group with 21 (32.3%) of 65 testing positive compared to 3 (8.5%) of 35 in the control group, indicating that this polymorphism is a probable risk factor for MetS in the Mexican population (odds ratio 5.0909, 95% CI 1.3977–18.5424, ). Our results may contribute to early diagnosis of MetS, which is essential for establishing changes in early stages of the disease to avoid further complications and pathologies, thereby preventing the development of type 2 diabetes and cardiovascular disease in Mexico.